RESUMEN
A new series of pyrazole-based factor Xa inhibitors have been identified as part of our ongoing efforts to optimize previously reported clinical candidate razaxaban. Concern over the possible formation of primary aniline metabolites via amide hydrolysis led to the replacement of the primary amide linker between the pyrazole and phenyl moieties with secondary amides. This was accomplished by replacing the aniline with a variety of heterobicycles, of which indolines were the most potent. The indoline series demonstrated subnanomolar factor Xa binding K(i)s, modest to high selectivity versus other serine proteases, and good in vitro clotting activity. A small number of indoline fXa inhibitors were profiled in a dog pharmacokinetic model, one of which demonstrated pharmacokinetic parameters similar to that of clinical candidate razaxaban.
Asunto(s)
Antitrombina III/síntesis química , Antitrombina III/farmacocinética , Inhibidores del Factor Xa , Indoles/química , Indoles/farmacocinética , Pirazoles/síntesis química , Pirazoles/farmacocinética , Antitrombina III/metabolismo , Antitrombina III/farmacología , Células CACO-2 , Diseño de Fármacos , Humanos , Indoles/farmacología , Unión Proteica , Pirazoles/farmacología , Relación Estructura-ActividadRESUMEN
Attempts to further optimize the pyrazole factor Xa inhibitors centered on masking the aryl aniline P4 moiety. Scaffold optimization resulted in the identification of a novel bicyclic pyrazolo-pyridinone scaffold which retained fXa potency. The novel bicyclic scaffold preserved all binding interactions observed with the monocyclic counterpart and importantly the carboxamido moiety was integrated within the scaffold making it less susceptible to hydrolysis. These efforts led to the identification of 1-[3-aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one 6f (BMS-740808), a highly potent (fXa Ki=30 pM) with a rapid onset of inhibition (2.7x10(7) M-1 s-1) in vitro, selective (>1000-fold over other proteases), efficacious in the AVShunt thrombosis model, and orally bioavailable inhibitor of blood coagulation factor Xa.
Asunto(s)
Inhibidores del Factor Xa , Pirazoles/farmacología , Piridonas/farmacología , Inhibidores de Serina Proteinasa/farmacología , Modelos Moleculares , Pirazoles/administración & dosificación , Pirazoles/química , Piridonas/administración & dosificación , Piridonas/química , Inhibidores de Serina Proteinasa/administración & dosificación , Inhibidores de Serina Proteinasa/químicaRESUMEN
Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P(1) ligand resulted in compounds with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P(4) moiety led to compounds with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compounds is described herein. These efforts culminated in 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide (11d), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clinical development as razaxaban (DPC 906, BMS-561389).
Asunto(s)
Inhibidores del Factor Xa , Fibrinolíticos/síntesis química , Imidazoles/síntesis química , Isoxazoles/síntesis química , Pirazoles/síntesis química , Administración Oral , Animales , Disponibilidad Biológica , Proteínas Sanguíneas/metabolismo , Células CACO-2 , Cristalografía por Rayos X , Perros , Fibrinolíticos/química , Fibrinolíticos/farmacología , Humanos , Imidazoles/química , Imidazoles/farmacología , Isoxazoles/química , Isoxazoles/farmacología , Modelos Moleculares , Permeabilidad , Unión Proteica , Pirazoles/química , Pirazoles/farmacología , Conejos , Relación Estructura-Actividad , Trombosis/prevención & controlRESUMEN
Factor Xa (fXa) is an important serine protease in the blood coagulation cascade. Inhibition of fXa has emerged as an attractive target for potential therapeutic applications in the treatments of both arterial and venous thrombosis. Herein, we describe a series of non-benzamidine isoxazoline derivatives as fXa inhibitors. The chloroaniline group was found to be the most potent benzamidine mimic in this series. Chloroaniline 1 (ST368) has a K(i) value of 1.5 nM against fXa and is highly selective for fXa relative to thrombin and trypsin.
Asunto(s)
Inhibidores del Factor Xa , Isoxazoles/síntesis química , Isoxazoles/farmacología , Animales , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Perros , Fibrinolíticos/síntesis química , Fibrinolíticos/farmacocinética , Fibrinolíticos/farmacología , Semivida , Humanos , Técnicas In Vitro , Indicadores y Reactivos , Isoxazoles/farmacocinética , Cinética , Modelos Moleculares , ConejosRESUMEN
Factor Xa (fXa) is an important serine protease that holds the central position linking the intrinsic and extrinsic activation mechanisms in the blood coagulation cascade. Therefore, inhibition of fXa has potential therapeutic applications in the treatments of both arterial and venous thrombosis. Herein we describe a series of tetrazole fXa inhibitors containing benzamidine mimics as the P(1) substrate, of which the aminobenzisoxazole moiety was found to be the most potent benzamidine mimic. SR374 (12) inhibits fXa with a K(i) value of 0.35 nM and is very selective for fXa over thrombin and trypsin.
